NCT05559905 Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) Status COMPLETED Phase PHASE2
NCT05558982 BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05557370 Immunogenicity of HPV Vaccine in Transplant Recipients. Status ACTIVE_NOT_RECRUITING Phase PHASE4
NCT05555732 Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05548621 A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC) Status RECRUITING Phase N/A
NCT05545969 Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma Status WITHDRAWN Phase PHASE2
NCT05530993 Exploring the Perspectives and Experiences of PrEP-eligible Black Women in Texas in Relation to Readiness for PrEP Uptake and Adherence Status COMPLETED Phase N/A
NCT05526716 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5) Status COMPLETED Phase PHASE3
NCT05525455 TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88) Status TERMINATED Phase PHASE1/PHASE2
NCT05524935 Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Status RECRUITING Phase PHASE2
NCT05523323 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension Status COMPLETED Phase PHASE3
NCT05514444 Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Status COMPLETED Phase PHASE1
NCT05508867 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) Status COMPLETED Phase PHASE2
NCT05507450 Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003) Status COMPLETED Phase PHASE2
NCT05504720 Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05496036 Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma Status RECRUITING Phase PHASE2
NCT05494736 MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004) Status COMPLETED Phase PHASE1
NCT05493618 Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. Status WITHDRAWN Phase PHASE1/PHASE2
NCT05491226 Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation Status RECRUITING Phase PHASE2